Janssen initiates study on erdafitinib intravesical delivery for bladder cancer in Japan
A clinical trial is underway to assess the tolerability of an intravesical delivery system for erdafitinib in Japanese patients with bladder cancer.
Company
Pharmaceutical intelligence for Janssen Pharmaceutical K.K. with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.